Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line

Journal of Pathology

Volumn 205, Issue 3, 2005, Pages 336-348

  Ritz, Olga ^a   Leithäuser, Frank ^a   Hasel, Cornelia ^a   Brüderlein, Silke ^a   Ushmorov, Alexey ^a   Möller, Peter ^a   Wirth, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Immunoglobulin silencing; Internal enhancer; Oct2; Primary mediastinal B cell lymphoma

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; IMMUNOGLOBULIN G; TRANSCRIPTION FACTOR;

ARTICLE; B CELL LYMPHOMA; CELL CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; ENHANCER REGION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOBLASTOID CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WESTERN BLOTTING;

DNA METHYLATION; DOWN-REGULATION; ENHANCER ELEMENTS (GENETICS); HUMANS; IMMUNOGLOBULINS; LYMPHOMA, B-CELL; MEDIASTINAL NEOPLASMS; NEOPLASM PROTEINS; ORGANIC CATION TRANSPORT PROTEINS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 13844297547     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1688     Document Type: Article

References (40)

1. Barth TF, Leithäuser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002; 3: 229-234.
2. Leithäuser F, Bauerle M, Huynh MQ, Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001; 98: 2762-2770.
3. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
4. Möller P, Brüderlein S, Strater J, et al. MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer 2001; 92: 348-353.
5. Rajewsky K, Kanzler H, Hausmann ML, Kuppers R. Normal and malignant B-cell development with special reference to Hodgkin's disease. Ann Oncol 1997; 2: 79-81.
6. Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 2001; 97: 3191-3196.
7. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162: 243-253.
8. Bentz M, Barth TF, Brüderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30: 393-401.
9. Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004; 29: 29.
10. Laumen H, Nielsen PJ, Wirth T. The BOB.1/OBF.1 co-activator is essential for octamer-dependent transcription in B cells. Eur J Immunol 2000; 30: 458-469.
11. Annweiler A, Muller-Immergluck M, Wirth T. Oct2 transactivation from a remote enhancer position requires a B-cell-restricted activity. Mol Cell Biol 1992; 12: 3107-3116.
12. Lernbecher T, Muller U, Wirth T. Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 1993; 365: 767-770.
13. Boehm J, He Y, Greiner A, Staudt L, Wirth T. Regulation of BOB.1/OBF.1 stability by SIAH. Embo J 2001; 20: 4153-4162.
14. Re D, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Deregulation of immunoglobulin gene transcription in the Hodgkin-Reed Sternberg cell line L1236. Br J Haematol 2001; 115: 326-328.
15. Kamesaki H, Fukuhara S, Tatsumi E, et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 1986; 68: 285-292.
16. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395-402.
17. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97: 496-501.
18. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001; 159: 1807-1814.
19. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-3134.
20. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18 943-953.
21. Zheng L, Roeder RG, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003; 114: 255-266.
22. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662-673.
23. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 2002; 62: 961-966.
24. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21 103-107.
25. Scarpa A, Moore PS, Rigaud G, Menestrina F. Genetic alterations in primary mediastinal B-cell lymphoma: an update. Leuk Lymphoma 2001; 41: 47-53.
26. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-2807.
27. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2004; 18: 11-17.
28. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18: 3063-3070.
29. Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002; 99: 3060-3062.
30. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004; 202 60-69.
31. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443-1450.
32. Kemler I, Bucher E, Seipel K, Muller-Immergluck MM, Schaffner W. Promoters with the octamer DNA motif (ATGCAAAT) can be ubiquitous or cell type-specific depending on binding affinity of the octamer site and Oct-factor concentration. Nucleic Acids Res 1991; 19: 237-242.
33. Schubart K, Massa S, Schubart D, Corcoran LM, Rolink AG, Matthias P. B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. Nat Immunol 2001; 2: 69-74.
34. Shah PC, Bertolino E, Singh H. Using altered specificity Oct-1 and Oct-2 mutants to analyze the regulation of immunoglobulin gene transcription. Embo J 1997; 16: 7105-7117.
35. Sen R, Baltimore D. In vitro transcription of immunoglobulin genes in a B-cell extract: effects of enhancer and promoter sequences. Mol Cell Biol 1987; 7: 1989-1994.
36. Wang J, Oketani M, Watanabe T. Positive and negative regulation of immunoglobulin gene expression by a novel B-cell-specific enhancer element. Mol Cell Biol 1991; 11: 75-83.
37. Wirth T, Staudt L, Baltimore D. An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. Nature 1987; 329: 174-178.
38. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10: 687-692.
39. Martinez-Delgado B, Melendez B, Cuadros M, et al. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 2002; 102: 15-19.
40. Malone CS, Miner MD, Doerr JR, et al. CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing. Proc Natl Acad Sci USA 2001; 98: 10404-10409.